PharmaShots | Incisive News in 3 Shots

Subscribe Now

 Finerenone

Bayer Submits MAA of Finerenone to Japan’s MHLW for Heart Failure (HF)

Bayer Submits MAA of Finerenone to Japan’s MHLW for Heart Failure (HF)

February 14, 2025

Bayer Submits MAA of Finerenone to the EMA for Heart Failure (HF)

Bayer Submits MAA of Finerenone to the EMA for Heart Failure (HF)

February 4, 2025

Bayer Reports the P-III (FINEARTS-HF) Study Data of Finerenone to Prevent Heart Failure with Preserved Ejection Fraction

Bayer Reports the P-III (FINEARTS-HF) Study Data of Finerenone to Prevent Heart Failure with Preserved Ejection Fraction

August 5, 2024

Bayer to Initiates P-III Study (FINE-ONE) of Finerenone for the Treatment of Chronic Kidney Disease and Type 1 Diabetes

Bayer to Initiates P-III Study (FINE-ONE) of Finerenone for the Treatment of Chronic Kidney Disease and Type 1 Diabetes

June 22, 2023

Bayer’s Kerendia (finerenone) Receives NICE Recommendation for Chronic Kidney Disease Associated with Type 2 Diabetes

Bayer’s Kerendia (finerenone) Receives NICE Recommendation for Chronic Kidney Disease Associated with Type 2 Diabetes

March 27, 2023

Bayer’s Kerendia (finerenone) Receives the US FDA’s Approval for New Label Update to Treat Chronic Kidney Disease and Type 2 Diabetes

Bayer’s Kerendia (finerenone) Receives the US FDA’s Approval for New Label Update to Treat Chronic Kidney Disease and Type 2 Diabe...

September 2, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us